TMS-fNIRS Personalized Dosing
NCT: NCT05916417 · ACTIVE_NOT_RECRUITING
Brief Summary
The intent of this study is to establish technical feasibility in a clinical population (PTSD, with or without mild TBI) of personalized TMS-fNIRS technology. Thereby demonstrating the utility of transcranial magnetic stimulation - functional near-infrared spectroscopy (TMS-fNIRS) technology as a direct measure of frontal brain activity, potentially replacing the indirect motor threshold procedure that may lead to improper dosing of TMS. Personalized TMS-fNIRS technology will guide therapy for depression, post-traumatic stress disorder (PTSD), and/or traumatic brain injury (TBI)
Frequently Asked Questions
What is TMS-fNIRS Personalized Dosing?
TMS-fNIRS Personalized Dosing is a clinical trial registered under NCT05916417. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05916417?
The current status of NCT05916417 (TMS-fNIRS Personalized Dosing) is: ACTIVE_NOT_RECRUITING.
When did TMS-fNIRS Personalized Dosing start?
TMS-fNIRS Personalized Dosing started on 2024-01-19.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.